{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:32:16Z","timestamp":1793460736945,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The National Cancer Institute\u00a0(NCI) identified survivorship research for people living with advanced and metastatic cancers as a priority in 2020. The goal of this portfolio analysis was to review all National Institutes of Health (NIH) grants newly funded in Fiscal Year\u00a0(FY) 2021\u00a0to FY 2024 focused on this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Grants were identified using a text mining algorithm of survivorship-relevant terms from the NIH Research, Condition, and Disease Categorization (RCDC) system and double coded for grant characteristics (e.g., study design, cancer type, primary focus, and primary outcomes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Included in this analysis were 63 grants, funded by 7 NIH institutes. The number of newly awarded grants funded rose from 9 in 2021 to 25 in 2024. The majority of grants were R01s (62.9%). Cancer types most often included were breast (22.2%), prostate (15.9%), and lung (15.9%). The primary focus of studies was most often acute toxicities (33.3%) or late- or long-term effects (33.3%). No grants focused on the financial impact of an\u00a0advanced or metastatic cancer\u00a0diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results indicate a substantial growth in the number of grants funded from FY\u00a02021 to FY\u00a02024. Grants address some of the gap areas identified in previous NCI efforts, including longitudinal studies of symptoms. Scientific gap areas that persist include financial hardship and employment, models of care delivery, and prognostic uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Cancer Survivors<\/jats:title>\n                    <jats:p>Despite the growth\u00a0in the grant portfolio, more research on survivors living with advanced and metastatic cancers is needed. This emerging population has unmet and understudied needs that will only expand given the growth in new therapies and targeted treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11764-025-01935-w","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:14:48Z","timestamp":1764731688000},"page":"2502-2508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re-examining survivorship research for people living with advanced and metastatic cancers: A portfolio analysis update of National Institutes of Health-funded grants"],"prefix":"10.1007","volume":"20","author":[{"given":"Michelle A.","family":"Mollica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Tesauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Tonorezos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gallicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1935_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae135","author":"E Tonorezos","year":"2024","unstructured":"Tonorezos E, et al. Prevalence of cancer survivors in the United States. JNCI J Natl Cancer Inst. 2024. https:\/\/doi.org\/10.1093\/jnci\/djae135.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1935_CR2","unstructured":"National Cancer Institute. Advanced Cancer. 2025 [cited 2025 October 23]; Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/advanced-cancer."},{"key":"1935_CR3","doi-asserted-by":"crossref","unstructured":"Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A, et al. Estimation of the number of individuals living with metastatic cancer in the United States. JNCI: J Natl Cancer Inst. 2022;114(11):1476\u20131483.","DOI":"10.1093\/jnci\/djac158"},{"key":"1935_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01573-8","author":"RS Brick","year":"2024","unstructured":"Brick RS, et al. Survivorship concerns among individuals diagnosed with metastatic cancer: findings from the cancer experience registry. J Cancer Surviv. 2024. https:\/\/doi.org\/10.1007\/s11764-024-01573-8.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"1935_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00520-024-08328-2","volume":"32","author":"MA Mollica","year":"2024","unstructured":"Mollica MA, et al. Financial toxicity among people with metastatic cancer: findings from the cancer experience registry. Support Care Cancer. 2024;32(2):137.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1935_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11764-021-01024-8","volume":"15","author":"J Lai-Kwon","year":"2021","unstructured":"Lai-Kwon J, et al. Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J Cancer Surviv. 2021;15(3):392\u20137.","journal-title":"J Cancer Surviv"},{"issue":"3","key":"1935_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11764-021-01008-8","volume":"15","author":"MA Mollica","year":"2021","unstructured":"Mollica MA, et al. Current state of funded National Institutes of Health grants focused on individuals living with advanced and metastatic cancers: a portfolio analysis. J Cancer Surviv. 2021;15(3):370\u20134.","journal-title":"J Cancer Surviv"},{"issue":"4","key":"1935_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jnci\/djab223","volume":"114","author":"MA Mollica","year":"2022","unstructured":"Mollica MA, et al. Survivorship needs for individuals living with advanced and metastatic cancers: a report from the 2021 National Cancer Institute meeting. J Natl Cancer Inst. 2022;114(4):489\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"1935_CR9","unstructured":"National Cancer Institute. RFA-CA-22\u2013027: Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional). 2022 [cited 2023 December 19]; Available from: https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/RFA-CA-22-027.html."},{"key":"1935_CR10","unstructured":"National Cancer Institute Office of Cancer Survivorship. Survivorship needs for individuals living with advanced and metastatic cancers. 2025 [cited 2025 July 25]; Available from:https:\/\/cancercontrol.cancer.gov\/ocs\/special-focus-areas\/metastatic-survivorship-needs. Accessed 25 Jul 2025."},{"key":"#cr-split#-1935_CR11.1","unstructured":"National Institutes of Health. Notice of Special Interest (NOSI): survivorship research for people living with advanced and metastatic cancers. 2025 [cited 2025 July 25]"},{"key":"#cr-split#-1935_CR11.2","unstructured":"Available from:https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-CA-25-024.html.\u00a0Accessed 25 Jul 2025."},{"key":"1935_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01414-0","author":"MA Mollica","year":"2023","unstructured":"Mollica MA, et al. Survivorship science at the National Institutes of Health 2017\u20132021. J Cancer Surviv. 2023. https:\/\/doi.org\/10.1007\/s11764-023-01414-0.","journal-title":"J Cancer Surviv"},{"key":"1935_CR13","unstructured":"National Institutes of Health. Grant Mechanisms. 2025 [cited 2025 October 23]; Available from:https:\/\/grants.nih.gov\/funding\/activity-codes\n. Accessed 30 Jul 2025."},{"key":"1935_CR14","unstructured":"National Cancer Institute. Office of Cancer Survivorship: definitions. 2025 [cited 2025 May 6]; Available from: https:\/\/cancercontrol.cancer.gov\/ocs\/statistics#definitions\n. Accessed 30 Sept 2025."},{"key":"1935_CR15","unstructured":"National Institutes of Health. Biological and social determinants of psychosocial sequelae in advanced head and neck cancer survivors receiving immunotherapy. 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/XU2L1a0d3U2dwIWwY6ywEw\/project-details\/10938261."},{"key":"1935_CR16","unstructured":"National Institutes of Health. A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors. 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/jsnoNfBVOU6I9Mj8g3hp2w\/project-details\/10929397."},{"key":"1935_CR17","unstructured":"National Institutes of Health. Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy. 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/M2iDJiuRFEmzTgNxZsWLGg\/project-details\/10934071."},{"key":"1935_CR18","unstructured":"National Institutes of Health. Randomized Phase II Trial of Prolonged Overnight Fasting and\/or Exercise on Fatigue and other patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer (FastER). 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/uCPlgxECIkqplzI6aVZeFQ\/project-details\/10714371\n.\u00a0Accessed 25 Jul 2025"},{"key":"1935_CR19","unstructured":"National Institutes of Health. Randomized clinical trial of a telemedicine-mHealth symptom cluster intervention for advanced cancer patients: Increasing access in underserved rural communities. 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/px1mSrrP40aP-VO3Bn7LmA\/project-details\/10938752."},{"key":"1935_CR20","unstructured":"National Institutes of Health. Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial Needs of Individuals Living with Likely Incurable Cancer. 2025 [cited 2025 July 25]; Available from: https:\/\/reporter.nih.gov\/search\/IRHseiH-FkeQOdFlj1bwOw\/project-details\/10936188. Accessed 30 Jul 2025"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01935-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01935-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01935-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:12:17Z","timestamp":1793459537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01935-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1007\/s11764-025-01935-w","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was prepared as part of the authors\u2019 official duties as employees of the US Federal Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Cancer Institute.","order":1,"name":"Ethics","label":"Disclaimers","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human subject participants were included in this project.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}